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Alzheimer's diseaseffects millions of persons worldwide. Earlier detection and/or diagnosis of AD
would permit earlier intervention, which conceivably could delay progression of this dementing disorder. In
order to accomplish this goal, reliable and speciﬁc biomarkers are needed. Biomarkers are multidimensional
and have the potential to aid in various facets of AD such as diagnostic prediction, assessment of disease
stage, discrimination from normally cognitive controls as well as other forms of dementia, and therapeutic
efﬁcacy of AD drugs. To date, biomarker research has focused on plasma and cerebrospinal ﬂuid (CSF), two
bodily ﬂuids believed to contain the richest source of biomarkers for AD. CSF is the ﬂuid surrounding the
central nervous system (CNS), and is the most indicative obtainable ﬂuid of brain pathology. Blood plasma
contains proteins that affect brain processes from the periphery, as well as proteins/peptides exported from
the brain; this ﬂuid would be ideal for biomarker discovery due to the ease and non-invasive process of
sample collection. However, it seems reasonable that biomarker discovery will result in combinations of CSF,
plasma, and other ﬂuids such as urine, to serve the aforementioned purposes. This review focuses on proteins
and peptides identiﬁed from CSF, plasma, and urine that may serve as biomarkers in AD.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder that
currently affects ﬁve million Americans. AD is the most common form
of dementia among the elderly, as approximately 50% of adults aged
85 years develop this condition. Diagnosis of AD is based on National
Institute of Neurological and Communicative Disorders and Alzhei-
mer's Disease and Related Disorders (NINCDS-ADRDA) Reagan criteria,
neuropsychiatric testing, neuroimaging such as PET scanning/MRI,
and an exclusion of other forms of dementia. AD is inherently difﬁcult
to diagnose, especially in very early stages when memory impairment
is mild and may go unrecognized. Despite intense investigation into
the mechanisms of neurodegeneration and possible causes of AD,
currently no cure or deﬁnitive underlying cause exists. Therapeutics
such as memantine, an NMDA receptor antagonist, and Aricept®, an
acetlycholinesterase inhibitor, slow the rate of degeneration and are
among the most widely prescribed medications to treat AD. These
drugs are effective only brieﬂy in the course of this disease and are
usually administered at a time when the patient has exhibited a
noticeable decline in cognition, and neurodegeneration has pro-
gressed to an irreversible state. Therefore, the need for a biomarker or
set of biomarkers to diagnose AD earlier, distinguish AD from other
forms of dementia, and monitor therapeutic efﬁcacy is of critical need1 859 257 5876.
l rights reserved.to aid and better protect the elderly from this devastating dementing
disorder.
A biomarker is an abnormal signal from a bodily ﬂuid or tissue that
can provide distinguishable pathological information for a patient.
According to the 1998 Consensus Report of the Working Group on
Molecular and Biochemical Markers of Alzheimer Disease [1], ideal
biomarkers for AD should be: 1) reﬂective or indicative of AD
pathology; 2) reliable; 3) easy to perform/analyze; and 4) relatively
inexpensive. Because biomarkers have the potential to assist in the
diagnosis, delineate the disease stage, andmonitor drug efﬁcacy in AD,
the notion of a single biomarker serving all of these functions is
somewhat unrealistic. Rather, a combination of markers for diagnos-
ing and managing AD and pre-clinical stages of AD, such as amnestic
mild cognitive impairment (MCI), are continually being investigated.
For AD and other neurodegenerative diseases, blood plasma and
cerebrospinal ﬂuid (CSF) have evolved as prime targets for biomarker
investigation. This review focuses mainly on proteins and peptides in
plasma and CSF as candidate biomarkers for AD, and brieﬂy discusses
advances in potential urinary biomarkers for AD.
2. Plasma
Plasma is the liquid portion of blood that suspends cells such as red
blood cells, white blood cells, and platelets. Plasma is pale-yellow in
color, rather viscous, and can be isolated from whole blood by
centrifugation at low speeds in the presence of an anticoagulant.
Serum, which is oftentimes confused with plasma, is plasma with
Fig. 1. Relative abundances of proteins in human plasma. Proteomic analysis of whole plasma is somewhat hindered due to the extremely high concentrations of some proteins
relative to others; depletion of high abundance proteins will enhance the dynamic range of plasma proteins present in low concentrations that may serve as biomarkers for AD and
other diseases.
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allowing blood to clot (therefore, no anticoagulant necessary) prior to
centrifugation. During the coagulation process for serum preparation,
the concentrations of some proteins in the sample are altered, and
also, protein fragments are released by platelets and other cells [2].
The plasma proteome, consequently, is altered and the opportunity for
artifactual results is increased. Also, high ﬁbrinogen levels have been
shown to be associated with cognitive decline in patients with MCI [3]
and increased risk of dementia [4]. With this protein removed from
the sample in serum preparation, a potential biomarker for ADmay be
overlooked. Therefore, depending on the investigation, plasmamay be
preferable for proteomic analysis/biomarker research instead of
serum.
The ease with which blood, and therefore plasma, can be obtained
from a human makes this ﬂuid ideal for biomarker investigation.
Human plasma is estimated to contain thousands of proteins and
peptides that span a dynamic range in concentration of N1015 [5].
Although an extremely rich source for disease-related biomarkers, the
concentrations of the most abundant proteins, the “classical proteins,”
make plasma a difﬁcult sample to analyze. Albumin, the most
abundant protein in plasma (albumin comprises greater than half of
the total plasma protein concentration), is capable of masking lower
abundance proteins that may be important as biomarkers. Depletion
methods for high abundance proteins have spawned a plethora ofFig. 2. Two-dimensional gel electrophoretogram of plasma before and after albumin and Ig
useful as biomarkers.commercially available dyes, spin cartridges, and high performance
liquid chromatography (HPLC) columns that are capable of depleting
approximately 20 of the most highly abundant proteins in plasma.
Thus, depletion of high abundance proteins will increase the
accessible dynamic range (Fig. 1) and uncover lower abundance
proteins that would otherwise be masked in a non-depleted sample
(for example, see the 2D electrophoretogram in Fig. 2).
3. Plasma biomarkers for differentiating AD from controls
In the last decade, numerous possible candidate biomarkers for AD
have been reported. A considerable number of AD studies of plasma
have exploited differences in the expression of individual proteins or
peptides in AD patients compared to healthy controls. Some of these
proteins have direct effects on brain/cognitive processes or are
localized in brain, and therefore fulﬁll the requirement that an ideal
biomarker be reﬂective of the pathology it represents. Also, because of
the multidimensionality of a biomarker, peptides or proteins
identiﬁed as having a characteristic difference in AD plasma may be
useful in other ways. For example, proteins indicative of pathological
conditions of AD may lead to new therapeutic strategies.
Numerous studies have identiﬁed plasma proteins whose expres-
sion levels in AD patients differ from controls. One proteomic study
found alpha-2-macroglobulin (α2M) and complement factor H (CFH)G depletion. Depletion of high abundance proteins unmasks protein spots that may be
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the increase for CFH was observed only for AD when compared with
other forms of dementia [6]. Both α2M and CFH have been shown to
be present in senile plaques [7,8], a hallmark of AD pathology. α2M is
associated with damage to the blood brain barrier (BBB) [9], which
may be evident in AD [10]. Also, α2M has been proposed as a genetic
polymorphism in AD [11,12].
Alpha-1-antitrypsin (A1AT), a serine protease inhibitor, was found
to be increased in AD plasma [13,14] and serum [15] compared to
controls and oxidized in its precursor form in AD [16]. A1AT is
localized in both senile plaques and neuroﬁbrillary tangles (NFT) [17].
The physiological role of A1AT is to suppress overexpressed proteases
during inﬂammation; oxidation of this protein can lead to an
alteration of its activity, and as a result, contribute to inﬂammatory
processes observed in conditions such as AD [18].
Alpha-1-antichymotrypsin (A1ACT) has been reproducibly found
to be increased in plasma/serum of AD patients compared to controls
[19–25], although some groups report otherwise [26,27]. A1ACT is a
serine protease inhibitor synthesized by the liver. Elevated levels of
this protein in the periphery may indicate the presence of systemic
inﬂammation [28]. Plasma and CSF A1ACT levels have been shown to
correlate with disease severity [29]. A1ACT is localized to senile
plaques observed in AD brain [30]. Interestingly, A1ACT differentially
interacts with Aβ(1–40) and Aβ(1–42), which could reﬂect the greater
neurotoxicity of the latter [31,32]. A1ACT also induces tau phosphor-
ylation in neurons, suggesting that this protein could contribute to
hyperphosphorylation and subsequent development of tangles [33].
Apolipoprotein A1 (APOA1), the main component of high-density
lipoproteins (HDL), has been reported to be lower in AD serum
compared to controls [34,35]. Themain function of APOA1 is to bind to
the ATP binding cassette transporter A1 (ABCA1) to promote
cholesterol export from cells and tissues into blood. Because ABCA1
is also present at the BBB, it has been suggested that lower APOA1
levels in serum may contribute to the pathogenesis of AD, due to the
involvement of cholesterol in APP processing [34]. Moreover, though
not proven yet, statins are proposed as a promising potential therapy
to Aβ, which conceivably could be related to APOA1.
Although these and other proteins may reﬂect pathological
processes observed in AD and have been identiﬁed as having
characteristic differences in diseased plasma compared to controls,
these differences have yet to achieve the diagnostic power, sensitivity,
and reproducibility necessary for widespread use in a clinical setting.
Reproducibility issues may arise in part due to different analytical
methodologies between laboratories, including choice of anticoagu-
lant and depletion strategy and storage among other considerations
that may affect the plasma proteome [150]. Therefore, standardization
using a valid universal protocol for sample handling and analytical
technique is essential before assessing which proteins are, in fact,
reproducible biomarkers of AD [36].
Amyloid-beta (Aβ) peptide is the central component of senile
plaques present in AD brain and exists primarily as 40- and 42-amino
acid peptides. Aβ can be detected via an enzyme linked immunosor-
bent assay (ELISA). Plasma Aβ levels have been shown to correlate
with age [37]; however, reports of Aβ differences in plasma on the
basis of AD diagnosis have found no signiﬁcant differences [38]. One
possibility for the broad overlap in plasma Aβ measurements may lie
in the analytical difﬁculties associated with this ﬂuid. For example, Aβ
is capable of binding to plasma proteins such as albumin [39]; in fact,
one study showed that 95% of Aβ present in the blood is bound to
plasma proteins, and therefore undetected by ELISA, probably due to
epitope masking [40]. ELISAs have been developed to detect total Aβ,
irrespective of being bound or unbound; however, some ELISAs only
measure “free Aβ,”which could possibly explain some group-to-group
variation [41].
A recent study in 2007 examined intra- versus inter-person
differences in plasma and serum Aβ levels [42]. Results of this studyshow lower intra-person than inter-person variability in plasma/
serum levels of Aβ. This suggests that, for measuring peripheral Aβ as
a potential marker, comparative studies of the same subjects before
and after diagnosis of MCI/AD may be more advantageous than one
comparing diseased subjects to normal controls, whichwould serve to
decrease between-group variability [42]. Nevertheless, levels of Aβ
have not yielded conclusive results in plasma to serve as a biomarker
for differentiating between AD and healthy controls.
4. Cerebrospinal ﬂuid
CSF is the “shock absorbing” ﬂuid that is produced by the choroid
plexus and bathes the space between the arachnoid and pia mater.
Approximately 500 mL of CSF is produced by the brain daily, which is
the same as its absorption rate into plasma [6]. The main functions of
CSF are to cushion the brain and spinal cord, and shuttle waste
products from the central nervous system into the blood. CSF is
obtained via lumbar puncture. Although lumbar puncture is invasive
and potentially painful for the patient, CSF is probably the most
informative obtainable ﬂuid for neurodegenerative disease prognosis.
For example, CSF hasmore physical contact with brain than blood, as it
is not separated from brain by the tightly regulated BBB. As a result,
proteins or peptides that may be directly reﬂective of brain speciﬁc AD
pathology would be most likely to diffuse into CSF than any other
bodily ﬂuid.
5. CSF biomarkers for differentiating AD and controls
Changes in brain chemistry may be reﬂected in CSF, since as noted
above, CSF is in direct contact with the central nervous system [43].
Analysis of CSF has produced some of the most reproducible
biomarkers for AD, such as decreased Aβ42, increased total tau (t-
tau), and increased phosphorylated tau (p-tau) [44–46]. Tau protein is
involved in tubulin polymerization and microtubule stabilization,
which helps maintain the cytoskeleton of neurons [47,48]. Tau protein
activity is regulated by phosphorylation and dephosphorylation by
various kinases and phosphatases; disruption of these events can lead
to hyperphosphorylation of tau, and assembly into neuroﬁbrillary
tangles (NFTs), one of the pathologic hallmarks of AD [49].
CSF t-tau is suggested to be a marker of neuronal death [50] due to
the fact that tau is an intracellular protein, and can diffuse into CSF as a
result of lysis of the neuron [51]. Also, CSF levels of t-tau are highest in
conditions known to exhibit severe neuronal damage, such as
Creutzfeldt–Jakob disease (CJD) [52]. Accordingly, investigators have
reported increased CSF levels of t-tau in AD [45]. Also, measurements
using ELISAs targeting six different phosphorylated epitopes of tau
have reported increases of p-tau in AD CSF compared to controls [45].
Interestingly, levels of p-tau are not elevated in CJD, despite such a
dramatic increase in levels of t-tau; this conceivably may be explained
by the absence of NFTs in brains of most CJD patients [53], which are
composed of hyperphosphorylated tau. CSF p-tau levels have been
suggested to be indicative of the phosphorylation state of tau, and
possibly reﬂect tangle burden in brain [54]. In fact, levels of p-tau231
in CSF have been shown to correlate with NFTs and hyperpho-
sphorylated tau load in several neocortical areas, namely frontal,
temporal, and parietal lobes [55]; however, there are recent reports of
no correlation between p-tau181 and neuroﬁbrillary pathology
[56,57]. Therefore, the role that CSF tau plays in the pathology of AD
requires more attention. Nevertheless, increased CSF t-tau and p-tau
have been shown to be reproducible markers in differentiating AD
from controls, and have potential for differentiating AD from other
dementia forms as well (see below).
Generally, CSF levels of total Aβ were not found to signiﬁcantly
differ between AD and control patients [58–60]. As mentioned
previously, Aβ42 levels in CSF are largely decreased in patients with
AD [46]. It was hypothesized that a reduction in CSF Aβ42 is a
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brain, with less diffusing into CSF [59]. Strozyk et al. reported that low
levels of Aβ42 correlated with high neuritic plaque load in both
neocortex and hippocampus [151]. Reductions in CSF Aβ levels that
correlate with Aβ deposition in the brain have also been observed in
the Tg2576 mouse model of AD [61]. However, this issue is still
controversial, as low levels of Aβ42 have also been found in dementias
without senile plaques [62], and Engelborghs et al. showed no
association between plaque burden and CSF Aβ42 levels in 50
autopsy-conﬁrmed AD cases [57].
Combinations of some CSF markers have also been successful at
discriminating AD from control cases. One study reported abnormally
high CSF p-tau/Aβ42 ratio has high sensitivity and speciﬁcity for
differentiating AD from normal controls [i.e., 86%/97% sensitivity/
speciﬁcity], and from subjects with other non-AD dementias [i.e., 80%/
73% sensitivity/speciﬁcity] [63]. Also, several studies have investigated
the usefulness of the Aβ42/t-tau CSF ratio in AD, which has been found
to discriminate AD from controls with high sensitivity but variable
speciﬁcity [45].
Proteomic studies in CSF have revealed proteins that show
expression/oxidation differences in AD patients versus controls. For
example, ﬁbrinogen gamma A-chain precursor was shown to be
increased in both AD and MCI patients compared to age matched
controls, and expression was dependent on the severity of dementia
[64]. Decreases in the concentrations of λ-chain, β-trace, and
transthyretin, as well as an increase in the carbonylation status of λ-
chain in the CSF of patients with probable AD have been reported [65].
Although differences in these and other individual proteins have been
exploited in CSF in AD [for review, see [66]], greater attention has been
given to tau and Aβ as potential biomarkers. However, Finehout et al.
recently reported a panel of CSF proteins using 2D gel electrophoresis-
based proteomics that distinguished between AD and non-AD with
sensitivities and speciﬁcities of 94%; this panel consists of proteins
involved in Aβ transport, inﬂammatory response, proteolytic inhibi-
tion, and in neuronal membrane, thus fulﬁlling criteria for a conclusive
AD biomarker [152]. A larger scale study will be needed to conﬁrm the
clinical usefulness of this panel in AD diagnosis.
6. Plasma/CSF biomarkers for AD prediction
AD pathology probably occurs 20–30 years prior to clinical onset
[67]. Patients diagnosed with amnestic MCI have a memory complaint
despite no observable signs of dementia. A signiﬁcant percentage of
patients with memory complaints that do not meet clinical criteria of
dementia are diagnosed as having MCI [68]. However, MCI diagnosis
does not imply that AD is 100% imminent, as other forms of dementia,
such as vascular dementia (VD), can be preceded by MCI [69]. Also,
some patients diagnosed with MCI revert back to a normal cognitive
state. A set of biomarkers capable of predicting dementia prior to
onset would have tremendous potential to improve the quality of life
of patients, namely, earlier treatment administration that would serve
to slow or possibly prevent dementia-related symptoms. Experimen-
tally, studies designed to determine protein/peptide alterations for
disease prediction and/or staging require long-term monitoring of
subjects from a cognitively normal or slightly impaired state
throughout the development of dementia.
Increased levels of CSF p-tau and t-tau, as well as decreased Aβ42,
have been reproducibly found to discriminate AD patients from
controls. While similar trends are also present in MCI patients
compared to controls [70], these individual differences have generally
not been capable of predicting AD in longitudinal studies, although
Ewers et al. report CSF p-tau231 as a good predictor of AD in MCI
patients [153]. On the other hand, combinations of biomarker levels
(along with some others) have proven to be effective in increasing
sensitivity and speciﬁcity of predictive AD diagnosis. A 1999 study by
Andreasen et al. revealed that high CSF concentrations of t-tau and/orlow concentrations of Aβ42 identiﬁed 14 of 16 MCI subjects who later
developed AD [71]. Another investigation supported the diagnostic
capability of thesemarkers, reporting 90% sensitivity and speciﬁcity of
predicting probable AD in MCI patients 18 months after the initial
diagnosis [72]. However, because MCI patients convert to AD at a rate
of about 15% per year [73], it is essential to investigate the diagnostic
capabilities of these markers over a longer follow-up period [44]. A
more recent investigation reported increased baseline concentrations
of CSF t-tau (N350 ng/L) and lower Aβ42 (b530 ng/L) predicted which
MCI patients would later (i.e., after 4–6 years) convert to AD with 95%
sensitivity and 83% speciﬁcity [68]. t-tau levels combined with the
Aβ42/p-tau181 ratio showed a slightly higher speciﬁcity for predicting
MCI to AD conversions [68]. A study of similar sample size and follow-
up time reports low Aβ42/40 ratios predict MCI to AD conversions
[74]; the Aβ42/40 ratio has been suggested to improve reliability of
dementia-related diagnosis compared to raw concentrations of Aβ
peptides [75]. Another report showed high CSF tau/Aβ42 ratios in
control subjects corresponded to increased frequency of the known
AD risk factor, the APOE4 allele, as well as increased risk for
conversion from healthy to MCI after a 42-month follow-up period
[76]. Levels of p-tau and Aβ42 at baseline were also capable of
predicting cognitive decline in healthy elderly adults, which may be
indicative of early AD signs [77].
As mentioned previously, plasma Aβ levels increase as a function
of age [37]. While total levels of plasma Aβ alone may seem rather
insigniﬁcant diagnostically in AD, low plasma Aβ42/40 ratios have
been associated with increased risk of developing MCI or AD [78]. A
case-cohort study in 2006 found that high Aβ40 and low Aβ42 in
plasma resulted in a greater than ten-fold increase in risk of
dementia [79]. Very recently however, Hansson et al. (2008) reported
plasma Aβ levels did not predict MCI to AD conversions in two sets of
cohorts, instead referring to CSF levels of Aβ42 as a much better
predictor of incipient AD [154].
Recently, Ray et al. proposed that, because the brain controls the
release and regulation of signaling proteins in the periphery, AD
pathology would have a disease-speciﬁc phenotype detectable in
plasma [80]. These researchers investigated the relative concentra-
tions of 120 signaling proteins in plasma using sandwich ELISAs and
report 18 proteins that were able to predict MCI to AD conversions, as
well as distinguish between AD and cognitively normal patients with
approximately 90% accuracy. Proteins involved in immune response,
apoptosis, hematopoeisis, and neuronal support were identiﬁed as
having characteristic concentration differences in plasma of subjects
with AD and in subjects with MCI who later developed AD [80]. It will
be interesting to see in the future if these protein changes in plasma,
possibly combined with predictive markers in CSF and brain imaging
techniques, will provide accurate enough results to allow for a
deﬁnitive clinical assessment of AD prior to onset of dementia.
7. Plasma/CSF biomarkers for differentiating between other forms
of dementia
One of the main criteria physicians use to diagnose AD is an
exclusion of other forms of dementia. Biomarkers capable of fulﬁlling
this criterion would greatly aid in the management and, possibly,
prevention of this disease. Unfortunately, some of the individual CSF
biomarkers capable of differentiating AD from normal aging are not
highly capable of differentiating AD from other forms of dementia. For
instance, while CSF levels of Aβ42 have been reproducibly found to be
decreased in AD patients relative to controls, a similar decrease has
been reported in dementia with Lewy bodies (DLB) [81,82], fronto-
temporal lobar degeneration (FTLD) [83], and amyotrophic lateral
sclerosis (ALS) [84]. Similarly, increased levels of CSF t-tau are evident
not only in AD but also in conditions with neuronal degeneration such
as CJD [52] and stroke [85], although levels of t-tau are so markedly
increased in CJD that they were able to differentiate CJD from AD
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a discriminatory marker for AD. High CSF levels of p-tau181 have been
shown to differentiate patients with AD from normal pressure
hydroencephalus [86] and DLB [87]. CSF p-tau231 levels discriminated
between frontotemporal dementia (FTD) and AD subjects with 88%
sensitivity and 92% speciﬁcity [88]. This marker was also capable of
differentiating between AD and geriatric depression, conditionswhich
are difﬁcult to distinguish clinically due to overlapping symptoms
[89]. CSF p-tau231 was signiﬁcantly higher in AD compared to FTD,
DLB, VD, other neurological disorders, and controls, and discriminated
AD from FTD with sensitivities and speciﬁcities greater than 90% [90].
p-tau combinedwith Aβ in CSF has yielded some promising results
for differentiation of AD from other neurological diseases as well.
Studies have shown an increase in the CSF p-tau/Aβ42 ratio as a
speciﬁc AD marker, including one that reported high degrees of
differentiation from normal controls, patients with other dementias
and patients with neurological disorders without dementia [63]. This
ratio was shown to distinguish AD subjects from FTLD, alcohol
dementia, and patients withmajor depression [91]. Consistently, a low
CSF Aβ42/p-tau ratio differentiated AD subjects from controls and VD
subjects with speciﬁcities and sensitivities greater than or equal to
85% [92], thus fulﬁlling the criteria for a reproducible biomarker;
however, an attempt to validate the ﬁndings of this study reported low
speciﬁcity using this ratio, which may limit differentiation between
VD and AD [93].
Another group of candidate CSF markers that has received some
attention for differentiation of AD from other dementia forms is that of
neuroﬁlament proteins. Three isoforms of neuroﬁlament proteins exist,
light, medium, and heavy chain, which together help form the axonal
skeleton. Similar to CSF t-tau, high levels of CSF neuroﬁlament proteins
also are thought to indicate neuronal death/axonal degradation [94,95].
Neuroﬁlament protein levels in CSF have been shown to be increased in
AD, but also in VD, FTD [96] and ALS [95]. De Jong et al. (2007) reported
that neuroﬁlament protein levels were increased in FTLD compared
with early AD (EAD), and when combined with p-tau181 and Aβ42
levels, increased diagnostic accuracy (i.e., sensitivity 86%, speciﬁcity
100%) [155]. Although somewhat promising, more insight is needed to
assess the discriminatory capacity of neuroﬁlament proteins in CSF.
No one protein/peptide biomarker or set of markers in plasma has
yet had the success of differentiating AD from other neurodegenera-
tive diseases in contrast to that in CSF. Increased plasma CD40, a
member of the tumor necrosis factor receptor superfamily, and a
concomitant decrease in TGF-β1 levels were found in AD patients, and
this trend was not observed in Parkinson's disease (PD) or non-AD
dementia patients [97]. De Servi et al. also observed decreased TGF-β1
in AD plasma compared to controls [156], although Rodriguez-
Rodriguez et al. reported no difference in TGF-B1 in serum between
AD and controls [157]. Serum brain-derived neurotrophic factor
(BDNF) was signiﬁcantly higher in AD compared to VD and controls
[98]. Levels of soluble receptor for advanced glycation end products
(sRAGE) were signiﬁcantly higher in plasma from AD patients
compared to VD as well [99]. However, more discriminatory studies
are needed to validate which plasma markers are speciﬁc only for AD.
8. Therapeutic effects on plasma/CSF biomarkers
The effects of AD and MCI therapeutics on plasma and CSF
biomarkers, particularly Aβ, are thought to provide useful informa-
tion for monitoring drug efﬁcacy. Aβ is central to the pathogenesis of
AD, as this peptide associates into oligomers and causes structural
and functional damage via oxidative stress mechanisms [100]. Thus,
many potential therapeutics are designed with the intention of
reducing the Aβ load in AD brain. Because the brain is in contact with
both CSF and plasma, changes in the Aβ content in brain may be
reﬂected in one or both of these compartments following pharma-
cological administration.8.1. γ-secretase inhibitors
Aβ is produced by sequential cleavages of the amyloid precursor
protein (APP) by two enzymes, β- and γ-secretase. β-secretase cleaves
APP ﬁrst at the N terminus, leaving a C terminal fragment (CTF)
spanning the inner membrane of the lipid bilayer. γ-Secretase
subsequently cleaves this CTF, releasing Aβ. Several therapeutics that
have been designed to reduce the Aβ load act by inhibiting γ-secretase.
The ﬁrst in vivo study of γ-secretase inhibitors reported decreased brain
Aβ in APP transgenic mice 3 h after oral administration [101]. Despite
showing potential as an AD therapeutic, the use of γ-secretase
inhibitors is questionable due to safety issues, as inhibition of γ-
secretase may have adverse health effects related to Notch signaling
[102]; however, some γ-secretase inhibitors are well tolerated by
patients in clinical trials and have potential as treatment for AD.
A few studies have examined plasma and CSF levels of Aβ after
administration of γ-secretase inhibitors. Administration of the γ-
secretase inhibitor LY450139 resulted in a 40% decrease in human
plasma Aβ40 [103,104]. Larger doses of this compound intensiﬁed this
effect, with a maximum 72.6% reduction in Aβ40 using a 140 mg dose
[105] that lasted for 12 h before returning to baseline. Decreases in
plasma, CSF, and brain Aβ40 have been observed in several rodent
species after administration of various γ-secretase inhibitors [106–
109]. Whether the decreases in plasma Aβ40 after administration of a
γ-secretase inhibitor is reﬂective of reduced neuronal Aβ is debatable.
Brain-derived Aβ is thought to inﬁltrate plasma via the actions of two
transporters at the blood brain barrier (BBB), low-density lipoprotein-
related protein 1 (LRP1) [110] and p-glycoprotein [111], as well as bulk
ﬂow from CSF/interstitial ﬂuid to plasma. Peripheral Aβ can also be
transported into the brain via the receptor for advanced glycation end
products (RAGE) [112]. While still controversial, recent studies have
reported that plasma Aβ levels do not reﬂect brain Aβ levels [113]. On
the other hand, plasma Aβ levels have been reported to decline along
with CSFAβ levelswhich correlates with Aβ deposition in the brains of
Tg2576mice [61]. Other cells, such as platelets, also produce Aβ, and it
would seem reasonable that γ-secretase inhibitors would affect this
source as well. However, Grimwood et al. report decreased plasma,
CSF, and cortex Aβ40 in guinea pigs after γ-secretase inhibition by
compound E [114]. Amarked decrease in plasma Aβ40was seen also at
lower doses of compound E, suggesting that one potential mechanism
for cortical Aβ40 reduction may result in part from a primary
reduction in plasma Aβ40 [114], which could lead to less being
transported into brain. Also, El Mouedden et al. reported reductions of
both Aβ40 and Aβ42 in rat plasma, CSF, and brain extract in a dose-
and time-dependent manner with an orally administered γ-secretase
inhibitor [158]. Therefore, it seems feasible that brain Aβ alterations
resulting from γ-secretase inhibitors could be detected in plasma
or CSF, though more investigation is necessary to decisively prove
this point.
8.2. Antibodies against Aβ
Another therapeutic strategy undergoing clinical trials for the
treatment of AD is immunization against Aβ. Lower levels of anti-Aβ
antibodies in AD patients versus controls led to the suggestion that
immunoglobulin therapy could be a viable treatment option [115,116].
Immunization can be active or passive; active immunity is the
production of antibodies via stimulation by an antigen, while in
passive immunity, pre-raised antibodies are directly administered to
the subject. Active immunization studies reportedly improved cogni-
tion and decreased cerebral amyloid deposits in transgenic animals
[117–119], but clinical trials in humans were halted after
the development of meningoencephalitis in a number of patients
[120,121].
While lower levels of Aβ antibodies were observed in AD patients
in some reports [115,122], other studies have contradictory results
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and antibody concentrations exists [124]. Based on this phenomenon
and the numerous variable reports on plasma Aβ levels in AD,
conﬂicting reports on the levels of antibodies against Aβ are not
surprising. As with Aβ ELISAs, epitope masking by the antigen (Aβ in
this case) may also contribute to the relative concentration variability
of this molecule in plasma/sera of AD patients. In this regard, a recent
report by Gustaw et al. details a method of dissociating Aβ-antibody
interactions for measurement of total titers in plasma or serum,
therefore circumventing this potential pitfall [124]. After dissociation,
signiﬁcant increases in Aβ antibodies were observed in plasma of AD
patients compared to controls, whereby the same analysis on non-
dissociated samples revealed no signiﬁcant differences [124]. Similar
investigations in plasma and CSF using this methodology may further
validate or refute immunotherapy as a treatment option for AD.
Nevertheless, immunotherapy has been reported to have positive
effects for AD patients and is brieﬂy reviewed here.
A small-scale investigation into the levels of Aβ in CSF and plasma
after passiveAβ immunization inmildADpatients revealed increases in
plasma Aβ40 and Aβ42, decreases in CSF Aβ40 and 42, and a 2.5-point
increase in mini mental state exam (MMSE) score after 6 months of
therapy [125]. Cessation of therapy resulted in CSF Aβ40 and Aβ42
increasing to pre-treatment baseline levels and a decrease in MMSE
scores after 3 months, and a decrease in CSF Aβ was observed again
when treatment was resumed after the three-month discontinuation.
Dodel et al. (2004) reported increased total serum Aβ and decreased
total CSF Aβ, as well as a slight general increase in MMSE scores as a
result of passive immunoglobulin therapy in mild to moderate AD
subjects [159]. However, safety is also an issue with passive immu-
notherapy, as cerebral hemorrhaging has been reported with this
treatmentmethod [126]. This side effect may beminimized by removal
of the Fc portion of the antibody against Aβ [127]. Nevertheless, if this
treatment passes clinical trials, CSF levels of Aβ may be a potential
biomarker to monitor intravenous immunoglobulin efﬁciency.
9. Urine-based biomarkers for AD
Urine is another bodily ﬂuid that has received attention for
biomarker investigation. This medium is less invasive to the patient
than plasma and CSF. While urine would be an ideal source for
biomarkers, analysis of this ﬂuid is difﬁcult due to very low protein
concentrations, high salt levels, and high overall variability [128]. Also,
many of the proteins that are excreted into urine are of low molecular
weight, thus rendering some proteomic strategies analytically
inappropriate [128]. Some published proteomic studies on urinary
biomarkers for AD have included non-protein species, such as
isoprostanes [129]. Nevertheless, neural thread protein (NTP) levels
have been reproducibly identiﬁed as an AD biomarker in urine, such
that speciﬁc NTP assays to urine have been developed as a diagnostic
tool [130,131]. A simple biochemical assay called AlzheimAlert® from
Nymox Pharmaceuticals measures levels of this protein in urine and
has reported sensitivity and speciﬁcity levels of N80% and 90% for AD
detection, respectively [149].
The NTP associated with AD, called AD7c-NTP, is substantially
increased in AD CSF relative to controls, and levels of this protein in
CSF seem to indicate the severity of dementia in early disease stages
[132,133]. This protein is overexpressed at the gene level in brains of
AD patients, accumulates in neurons with disease progression, co-
localizes with senile plaques found in AD brain, and impairs
mitochondrial function and causes apoptosis in vitro [133]. AD7c-
NTP is detected by ELISA, and is increased in urine of patients with
early AD [131,133]. The urinary concentration of this protein also
increases with disease severity consistent with analysis of AD7c-NTP
in CSF [131,133]. While the discriminatory power of this protein in
urine has yet to be established, levels in CSF in patients with MS,
multi-infarct dementia, CJD, PD, diffuse LBD, and Pick's disease weresimilar to controls [132,133], which may be evident in urine but has
yet to be reported. Effects on the levels of AD7c-NTP in urine after
therapeutic intervention also remain to be investigated.
10. Potential effects of lifestyle on biomarker levels
It is feasible that certain lifestyle factors could inadvertedly affect
biomarker levels, speciﬁcally diet, medication, and exercise. From a
dietary standpoint, antioxidant-rich diets would seemingly quench in
vivo markers of oxidation in AD, namely isoprostanes as well as
oxidized proteins serving as markers in either plasma or CSF.
Cholesterol effects on brain Aβ would presumably affect the brain-
derived contribution of this peptide to CSF, and possibly plasma as
well. CSF levels of Aβ42 were decreased in guinea pig after treatment
with simvastatin [134]. However in patients without dementia,
treatment with simvastatin and pravastatin for 14 weeks did not
signiﬁcantly alter CSF levels of either Aβ40 or 42 or t-tau [135]. Other
studies also conﬁrm steady Aβ and t-tau levels with statins [136,137],
although some reports differ with respect to p-tau [135,136]. NMDA
receptor antagonists prevent against excitotoxicity, and therefore, cell
death; while not yet proven, these agents may in fact lower t-tau CSF
levels, proposed markers of neuronal death. If this were true, t-tau
levels in CSF may be an indicator of in vivo efﬁcacy of drugs such as
memantine. However, Degerman Gunnarsson et al. found signiﬁcantly
reduced CSF p-tau with memantine treatment, whereas t-tau and Aβ
were unaffected [138]. Because the signiﬁcance of p-tau levels in CSF is
still debatable, the implication of this decrease in CSF remains to be
investigated. Meanwhile, cholinergic agents were the subject of a
2002 investigation that probed CSF levels of Aβ, t-tau, and p-tau and
no signiﬁcant differences in these biomarkers were observed in
patients after treatment with donepezil, rivastigmine, or galantimine
[139].
Physical activity is believed to play a preventative role in AD.
Several groups have shown that increased physical (and intellectual)
activity decreases risk of dementia [140,141], although some studies
do not support this idea [142]. Also, investigations using mouse
models of AD have shown cognitive improvements and/or decreased
brain Aβ in mice exposed to exercise [143–146]. It has been reported
that environmental enrichment has cognitive, behavioral, and
biochemical beneﬁts [147,148]. Decreases in brain Aβ could have
downstream consequences on the levels of this peptide in other
bodily ﬂuids, however the extent of this effect is not known at this
time.
11. Conclusions
Biomarkers have many advantages for managing and predicting
AD. As mentioned previously, it is estimated that pathology in AD
begins roughly 20–30 years prior to diagnosis; early diagnosis would
shift the dynamic of treatment from slowing neurodegeneration to
potential prevention, so that the patient would bemore likely to die of
natural causes and perhaps other factors, rather than AD. Markers
sought in plasma or urinewould be advantageous due to the easewith
which the sample is obtained; however, to date, it appears that more
reproducible markers have been found in CSF. On the whole,
speciﬁcities and sensitivities of diagnosis seem to increase using
combinations of CSF biomarkers as opposed to absolute values of a
single marker. Moreover, it is reasonable to believe that the outcome
of these studies will result in combinations of plasma, CSF, and/or
urine biomarkers that will serve diagnostic, staging, and therapeutic
purposes in AD.
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